Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.
In this segment of the video discussion focused on hepatocellular carcinoma (HCC), Kim and the panel of medical experts delved into the complexities of health care resource utilization and associated costs in HCC treatment strategies. The multidisciplinary nature of HCC treatment was emphasized, with discussions on the involvement of various specialists such as medical oncologists, hepatologists, and the need for comprehensive care in tertiary centers. The significance of preventing liver cirrhosis, hepatitis B, and hepatitis C was underscored as a potential cost-saving measure, with the panel advocating for the integration of preventive strategies such as vaccination and antiviral therapies to curtail the progression of HCC.
The conversation expanded to the interplay between value-based care principles and health care resource utilization. Kim shed light on the significance of striking a balance between effective treatment outcomes and managing the costs and resource utilization associated with HCC therapies. The experts stressed the importance of considering the burden on the patient and the potential impact on their quality of life when evaluating treatment options, underlining the need for patient-centric approaches in HCC management.
Furthermore, the panel emphasized the judicious use of diagnostic procedures and imaging studies, cautioning against overreliance on sophisticated imaging techniques when clinical examinations could suffice. They advocated for a streamlined and pragmatic approach to diagnostic processes to avoid unnecessary radiation exposure and minimize health care costs without compromising the quality of patient care. The experts urged health care providers to adhere to standardized practices and minimize redundant tests, emphasizing the need to optimize the use of health care resources for the benefit of HCC patients.
Throughout the discussion, the experts’ insights reflected a comprehensive understanding of the challenges and opportunities in HCC treatment, underscoring the importance of preventive measures, cost-effectiveness, and patient well-being. Their discourse provided valuable guidance for health care practitioners and policymakers alike, seeking to optimize HCC treatment strategies while efficiently utilizing health care resources.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New AI Tool Identifies Undiagnosed PNH in Health Records
October 30th 2024The machine learning model shows promise in detecting paroxysmal nocturnal hemoglobinuria (PNH) by assessing electronic health records (EHR) data, potentially transforming the diagnostic landscape for rare diseases.
Read More
Zanubrutinib More Effective Than Ibrutinib in Treating Patients With Relapsed/Refractory CLL, SLL
October 30th 2024The long-term response rate for zanubrutinib was better than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Read More